{"name":"Glaukos Corporation","slug":"glaukos","ticker":"GKOS","exchange":"NYSE","domain":"glaukos.com","description":"Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal deliver","hq":"San Clemente, CA","founded":0,"employees":"1094","ceo":"Thomas Burns","sector":"Ophthalmology / Medical Devices","stockPrice":119.87,"stockChange":4.81,"stockChangePercent":4.18,"marketCap":"$7.0B","metrics":{"revenue":507442000,"revenueGrowth":35.7,"grossMargin":78,"rdSpend":49676000,"netIncome":-187691000,"cash":90813000,"dividendYield":0,"peRatio":276.2,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"1953-01-01","label":"Infuvite Pediatric first approved","drug":"Infuvite Pediatric","drugSlug":"riboflavin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Infuvite Pediatric","genericName":"RIBOFLAVIN","slug":"riboflavin","indication":"Mineral Deficiency Prevention","status":"marketed"}]}],"pipeline":[{"name":"Infuvite Pediatric","genericName":"RIBOFLAVIN","slug":"riboflavin","phase":"marketed","mechanism":"Flavin reductase (NADPH)","indications":["Mineral Deficiency Prevention","Mineral deficiency","Vitamin Deficiency Prevention","Vitamin deficiency"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Glaukos Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Glaukos reported fourth quarter and full year 2023 financial results, with revenue increasing 14% year-over-year.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Glaukos Announces Strategic Partnership with Alcon","summary":"Glaukos announced a strategic partnership with Alcon to develop and commercialize its iLink and iDose systems in the United States and Europe.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Glaukos Receives FDA Clearance for iLink and iDose Systems","summary":"Glaukos received FDA clearance for its iLink and iDose systems, expanding its product portfolio for glaucoma treatment.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNakxIa3BFdFFJQW03bG15czlfbjhpWWJzU1NxYlZMZmpfUkU1ZnU1eldjcjJJdFlfVnN4UlVXbGFXTm1DVi1kV2h2TnNrbkdLcEcyZER2M1VzRC1yWE9ab0dTLVk5VE9IcHNfWnlGQ2ZaaURhUTM0RUEtdXdSVk1xamRMNlVQTlVsdjFIcnZVbEg3emVqZ2JHNkIzMU5wbkIwRWo4cFB5akM1a2xiY2lvbnk4cFcxbEdoeU56YzVYbjY?oc=5","date":"2026-04-08","type":"earnings","source":"Stock Titan","summary":"Glaukos sets April 29 earnings release, webcast after market close - Stock Titan","headline":"Glaukos sets April 29 earnings release, webcast after market close","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPZWotNjNWbDJjUWJZQ2pZWjQxakJLZFFTUnpFWnNSdU85LS1LSEdwY0RKS2dTV2hRTDFodHNnRGR5REhiX2xEbTZNMVAyWmdwbE5FV1R5bUU1U3c2ek9XWGJodWszaWd6ZWdBYldxeGZUSkVETEZtR0FWVkxpXzZWRm1nZ0VGYzQ3LTJIdWZEVWh4NE1ZU29SaXhCekRabjh3eHY2OXpLU1J0Q3ZfZlE?oc=5","date":"2026-02-18","type":"earnings","source":"BioSpace","summary":"Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results - BioSpace","headline":"Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPWmFmVXhQM3QtdWVlNVB3M2tiWkUydHpVY3p0RmZDX2RocWlQdEFBWl9nU2tLeEF6Z0pWbEtYTU5KZEVCbjBZS1QxYzJLRUZzR080U09zLXRnTmJVdGpRTm9rYXV3MU1uUXVVR2t6OU9lcTU2OE5aYkxfcjBrQXg0UnVQMmlCZ0ZoYzIxUjA0ZXJGS255SmozU2NOa19JcVZYSHNKRzdKSVI3MzNhSE8tejNIVC1IaDQ2Z2k4VQ?oc=5","date":"2026-01-29","type":"pipeline","source":"TradingView","summary":"Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - TradingView","headline":"Here's Why You Should Retain Glaukos Stock in Your Portfolio Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQdzVoOVFucDFHQnJEMk5hZ2ZZUVJqTkNJazBwSHFxSjB1V0F0LXFoY2Q0bmtPZ3V4Z282dFBfNEdTdm5ROGdsOThoWWFBN0VDSVVsdjVXY0kyZXMwNncwcmt3WmdJQUZPVFhOcmlfc05GRVg5ZnFreUxwbW5jZkFWeTNYMURDYWpSQXV4Szk3andrMk5mRHVhV3VXQnJpdHRNRzRrVVdXeXJIR2xtMVpscVRPSUhfdHdrZG51NElsazc1QjJJdTFZMmd1SHpKNXVJbmJUamJGdGVtM21TODU2aVItWkdsUQ?oc=5","date":"2026-01-28","type":"regulatory","source":"Business Wire","summary":"Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR - Business Wire","headline":"Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOSlp6UkFUajdRRDRBYnRzZ25JemNKbGhLZlhQOHN6VzZGSkNrcTVNQ2hOX3NhQ2hRRkZrZldFcnpfSEZuUHJETy14R3lidmhlbmJSVGtUM1Z4cTRGOHc5SjFEbE1rUDkwaGl4aFBBcW85M05UNDhoVTRXamN0OUxyc1VhUVlXOV9Bbng4MjBBdEs2ZHg1c2FJM0hnaWx2Wm9VcHpvbWF0cnRpYUdrSERTYmZnRTRMUU5o?oc=5","date":"2026-01-20","type":"pipeline","source":"Stock Titan","summary":"Glaukos sets Feb. 17 call to review 2025 results, eye disease focus - Stock Titan","headline":"Glaukos sets Feb. 17 call to review 2025 results, eye disease focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxORzRlVFZickhOa0Z1YkY1Z0JyeElPcWxvUGluNHFDQWhNVTZUOVI3RUlDdU8xcVJSMVl1WE4wUnd0Wm1YRVNUcGNkOGZQUmc2ZEVDaDVQdmNLMGRLM1RhSG9Jem9Wc1VxSWFLS2ZFaERjUWF4MzYxWmxiU1M5d2JDZ3ZXMXRVOElBdDlkdno4NUF4cXNQUXpkWjlwYUZFSTdsdnJjN1A1cGozTTUyb2U5dEgtRklHaHFfRkp3TFlIcXJuNFBQQW9RdERySkZRaEZ3cDhMN0RxQ3hsRExaVm1BUDAzMnM?oc=5","date":"2026-01-14","type":"pipeline","source":"Benzinga","summary":"Glaukos, Trip.com Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga","headline":"Glaukos, Trip.com Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNVG9qVDhyQXNSWXBHQlZRLXRLb3dUV0pwYld5ckh3clgzWlNVSE0xcGxiSjRld1dDUE5TYWpiX3ZpaEFZN1hGZEFORjJJYnpvMEt1UFFCN1NTcVpsZ3NWVFJWb3VGbE9yeVhnMTZ6Qmxid0YwWlJsaHV5QmludDNoYWI4RmpLcFZsT0NUOVRoQzliYnoxUGE4ZnFrRTlVSHFVOVhYeG00MGxkQUNWeFFGVmVtRlpmQkxjVWpiOXUxbDk1d0tGNGxIMUt6V0c3UE1Iak5lWHlWNTlFX2xRX290NWtpZ3BUYjd3NHI0R2xNcFE0dUZKX004azJZNWlPaFNiWkRwd1JXdw?oc=5","date":"2026-01-13","type":"earnings","source":"Business Wire","summary":"Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance - Business Wire","headline":"Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSHZyMXBQb3lNeTRIRkdxNjNsSk16dEZCeS1rbXEtXzAxNHhfRDFYSnJ0bmFkN2lJZ0JaVFFlbmd1dlZ4Z1ROMGl6blpjWTVOVEpvMXZGZ1JSZWhoR3QxX0Z4M0VjaGFURjJPbWV0SlpqS0xXR09ZeldyTjdUdjFSZmo1eFgzdm1TQjhFTWc4U3M5bWRFOWdOdUFUSlZTMjlaQ0FZd3dRWFZGeHN6MHlBTkl4TUEzMUJsUkpScU9fZjE4Uzg?oc=5","date":"2025-12-16","type":"pipeline","source":"Business Wire","summary":"Glaukos Announces Participation in J.P. Morgan Healthcare Conference - Business Wire","headline":"Glaukos Announces Participation in J.P. Morgan Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPSHBTZkl2YkY1ZlR5dXBJSVYxM1NkZ3hYUk16WGlQUml6NWhyQjgwMXg0WF9DVXYwNFBzVjJoam1WMEJfUUVScTliZV9PVUlGcVNwV2JzdkdxOVFreHZBbENvN3J0cDBvaWFUMlZqcFhrTU1SakU4VGdVVUZuSW9FR1lhVXJLUnFqMEdBRFp2YlZJUmI0a0RjaWVPZlFhQTdUT0d5ZDZ6c180WDJzQm5TWnFGSQ?oc=5","date":"2025-10-21","type":"regulatory","source":"RTTNews","summary":"Glaukos: Epioxa Approval And Pipeline Momentum Highlight Ophthalmic Expansion - RTTNews","headline":"Glaukos: Epioxa Approval And Pipeline Momentum Highlight Ophthalmic Expansion","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPeTV3QVdtVkVCTl8tNDBwLU1na1JReFU1Y2xBeWhDRjA5dzVPZjhncmx4MS1EbEtoeFMxOENmUDlMMTZ2Si1yOW94WjloNWFtdUxNaVJCQWtILWNEZGtlRG1jVnk3QnZiOUF1NTl4eVdxQ0F1MnF6MzZZakxkaTQ4NGMtNF9fOFJjVnRRdGZpeGZKNUtlZnlZemxKNDVPQU0waEhTWUtZUDJ5enFqOHYzWQ?oc=5","date":"2025-10-20","type":"regulatory","source":"Reuters","summary":"US FDA approves Glaukos' new eye therapy - Reuters","headline":"US FDA approves Glaukos' new eye therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPWXcxSk1OOG10V0ZkNG1XWFNxRFpQZ19lWHFIeXZXNW1hdExfS2FCdU5OWWtaXzhMeTFDY292QjlyV1BDQlZvaWJ3SGszckl5QVlDaG12LVZHLVB5NWVqa1dOYmlUOHdDWjJIdVZlLTdPSHZTLURZcXhwUi1LUTVDbk9DaWlESUJpNmRZQ2NEMGt1Q2U4M0V4eklqMC14eW5nV0xfRTFIOHJlaWJRNWNCQjNNYTE0ZFhPSkxKa1ZXYlFBN1REVDIzbjZjbjlBc3VnX0xRbw?oc=5","date":"2025-09-25","type":"pipeline","source":"BioSpace","summary":"Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama - BioSpace","headline":"Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOUHFKOW5lbEotcVB2X09zQmFNbmtfZTRXNmhuOXpCd2VxSmF5djVYaUxEblpya1ZDOGNRZXZ3UHZENVhvbmRyNW1VajZTNW5Eb185LUtwRTZNTHFBWkxsOWo0TlhEczJHSE4zWXlYbTR6b2JhVi0wM1F3d1Y5NF9IZ2NhamwzU2o3Rm4wcg?oc=5","date":"2025-09-18","type":"regulatory","source":"Yahoo Finance","summary":"Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa - Yahoo Finance","headline":"Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alcon","Johnson & Johnson","Abbott Laboratories"],"therapeuticFocus":["Glaucoma","Ophthalmology"],"financials":{"source":"sec_edgar","revenue":507442000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":507442000,"period":"2025-12-31"},{"value":383481000,"period":"2024-12-31"},{"value":314711000,"period":"2023-12-31"},{"value":282862000,"period":"2022-12-31"},{"value":71269000,"period":"2022-09-30"},{"value":72685000,"period":"2022-06-30"}],"grossProfit":282761000,"grossProfitHistory":[],"rdSpend":49676000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-187691000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":90813000,"cashHistory":[],"totalAssets":893487000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":119.87,"previousClose":115.06,"fiftyTwoWeekHigh":130.23,"fiftyTwoWeekLow":73.16,"fiftyTwoWeekRange":"73.16 - 130.23","fiftyDayAverage":111.93,"twoHundredDayAverage":100.01,"beta":0.78,"enterpriseValue":6507111424,"forwardPE":276.2,"priceToBook":10.51,"priceToSales":13.72,"enterpriseToRevenue":12.82,"enterpriseToEbitda":-133.78,"pegRatio":0,"ebitda":-48640000,"ebitdaMargin":-9.6,"freeCashflow":1400000,"operatingCashflow":-14789000,"totalDebt":106545000,"debtToEquity":16.2,"currentRatio":4.69,"returnOnAssets":-5.8,"returnOnEquity":-26.4,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":12,"targetMeanPrice":138.75,"targetHighPrice":165,"targetLowPrice":120,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.2,"institutionHeldPercent":100.6,"sharesOutstanding":58078812,"floatShares":55749097,"sharesShort":2673825,"shortRatio":3.45,"shortPercentOfFloat":4.6,"epsTrailing":-3.28,"epsForward":0.43,"revenuePerShare":8.87,"bookValue":11.41,"officers":[{"age":64,"name":"Mr. Thomas William Burns","title":"Chairman & CEO"},{"age":48,"name":"Mr. Joseph E. Gilliam","title":"President & COO"},{"age":54,"name":"Mr. Alex R. Thurman","title":"Senior VP & CFO"},{"age":48,"name":"Dr. Tomas  Navratil Ph.D.","title":"Chief Development Officer"},{"age":null,"name":"Mr. Christopher William Lewis","title":"Vice President of Investor Relations & Corporate Affairs"},{"age":59,"name":"Mr. Robert L. Davis J.D.","title":"Senior VP, General Counsel & Business Development"},{"age":null,"name":"Ms. Diana A. Scherer","title":"VP of Compliance & Deputy General Counsel"},{"age":null,"name":"Ms. Michele M. Allegretto","title":"Senior Vice President of Human Resources"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.glaukos.com","phone":"949 367 9600"}}